Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company ArmaGen Inc.
DescriptionAlpha-L-iduronidase (IDUA) fused to an IgG that targets insulin receptors (INSR)
Molecular Target Insulin receptor (INSR)
Mechanism of ActionEnzyme replacement therapy
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase II
Standard IndicationMucopolysaccharidosis
Indication DetailsTreat mucopolysaccharidosis I (MPS I, Hurler syndrome)
Regulatory Designation U.S. - Rare Pediatric Disease (Treat mucopolysaccharidosis I (MPS I, Hurler syndrome))

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today